PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Anesthesiology and Intensive Care, University of Leipzig Medical Center, Leipzig, Germany.\', \'Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.\', \'Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.\', \'Centre for Biological Threats and Special Pathogens (ZBS), Strategy and Incident Response, Clinical Management and Infection Control, Robert Koch Institute, Berlin, Germany.\', \'Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.\', \'Department of Respiratory Medicine, Christian Medical College, Vellore, India.\', \'Department of Pulmonary Medicine, Christian Medical College, Vellore, India.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1002/14651858.CD015125
?:hasPublicationType
?:journal
  • The Cochrane database of systematic reviews
is ?:pmid of
?:pmid
?:pmid
  • 35262185
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Inhaled corticosteroids for the treatment of COVID-19.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all